Suchergebnisse - "Zingman, Barry S"

PubPharm (6)

1

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders

enthalten in: Therapeutic drug monitoring | 2011

von Ma, Q. | Zingman, B. | Luque, A. | +6

2

Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects : 48-week results of the VICTOR-E1 phase 2 trial

enthalten in: The Journal of infectious diseases | 2010

von Suleiman, J. | Zingman, B. | Diaz, R. | +8

CommentIn: J Infect Dis. 2011 Jan 15;203(2):292; author reply 293. - PMID 21288830

3

Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy

enthalten in: HIV clinical trials | 2009

von Shuter, J. | Sarlo, J. | Rode, R. | +1

4

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users

enthalten in: Journal of pharmaceutical and biomedical analysis | 2007

von DiFrancesco, R. | Fischl, M. | Donnelly, J. | +6

5

HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2007

von Shuter, J. | Sarlo, J. | Kanmaz, T. | +2

6

Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors : validation and application

enthalten in: Therapeutic drug monitoring | 2007

von Keil, K. | Hochreitter, J. | DiFrancesco, R. | +5

1
[1]